bevacizumab,paclitaxel,carboplatin,durvalumab,olaparib
astrazeneca,roche,merck
['ovarian', 'imfinzi', 'lynparza', 'duo-o', 'astrazeneca']
at #asco23, duo-o trial s imfinzi and lynparza in advanced #ovariancancer raises the prospects of an immunotherapy option, but also a lot of questions 
https://t.co/O0ZJQGuINh, and its digital magazine Deep Dive, is a leading online destination for healthcare and pharmaceutical industry news, insight and debate